Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Dr. Giovanni Caforio M.D.

Market Cap

99.65 Billion USD

Sector

Healthcare

Website

https://www.bms.com

Last Update

2/22/2024, 12:00:00 PM

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.

Read More

Overview

Value

69

Growth

55

Health

53

Management

56

Analyst Opinion

97

Total

60

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Price-to-earnings ratio of 13.6 is lower than the market average (19.6x)
  • Has a margin-of-safety above fair value
  • Liked by analysts
  • Has strong dividend growth
  • Very safe dividend

Risk Factors

  • There is a history of diluting shareholders
  • Disliked by Twitter users

Market Peers

BMY

Key Figures

PE Ratio (TTM)

13.57

Margin Of Safety (DCF)

122.89%

Revenue Growth (5 Year Average)

12.13%

Ratings Consensus

Strong Buy

Share Buybacks

-5.53%

Dividend Yeild (TTM)

4.46%

Valuation

Value Score

69

  • Price-to-earnings ratio of 13.6 is lower than the market average (19.6x)
  • Free-cashflow-yeild of 11.88% is better than the market average (4.7%)
  • Margin-of-safety of 122.89% is better than the market average (17.95%)
  • Estimated intrinsic-value of 117.35 USD is higher than current price ( 49.16 USD)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 77.6 USD

Current Price: 52.7 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

13.57x

Free Cashflow Yeild

11.88%

PE/Earnings Growth

N/A

Price/Book

3.61x

Growth

Growth Score

55

  • 5 Year Average Revenue growth of 12.13% is higher than the market average (10.97%)
  • Earnings growth has improved this year
  • 5 Year Average Cashflow growth of 18.32% is higher than the market average (12.35%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of 8.63% is lower than the market average (14.48%)
  • Free Cashflow growth has slowed this year

Revenue Growth

12.13%

Earnings Growth

8.63%

Cashflow Growth

18.32%

Health

Health Score

53

  • Assets cover liabilities
  • Debt repayments do not significantly impact cashflow
  • Has a high level of debt
  • Requires debt for normal operation to be sustainable

Altman Z Score

2.30

Piostroski Score

7.00

Debt/Equity

1.27x

Current Assets/Liabilities

1.25x

Free Cashflow/Total Debt

0.30x

Debt/Capital

1.44x

Dividend

Secure Dividend Score

74

  • Dividend yeild of 4.46% is more than the market average (1.85%)
  • Very safe
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Long term dividend payout ratio of 79.64% is high and may limit growth
  • Payout ratio (TTM) of 59.12% is higher than the average (40%)
  • Dividend growth has been slowing recently

Dividend Yeild

4.46%

Dividend Growth

5.41%

Payout Ratio (Earnings)

59.12%

Payout Ratio (Cashflow)

37.50%

Management

Management Score

56

  • Has returned higher dividends when earnings have risen
  • Return-on-equity of 19.34% is higher than the market average (15%)
  • Return-on-capital-employed of 23.69% is higher than the market average (10%)
  • Has issued new shares whilst share price is low
  • Has a history of diluting shareholders to finance activity

Average Buybacks/Dilution

-5.53%

Recent Buybacks/Dilution

-6.08%

5 Year Price Volitility

14.10%

Return On Assets

6.20%

Return On Capital Employed

23.69%

Return On Equity

19.34%

Return On Free Cashflow

N/A

Return On Investments

N/A

Social Sentiment

Social Sentiment Score

28

Twitter Sentiment

0.00

Stocktwits Sentiment

56.00

Analysts

Analyst Opinion

97

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Bristol-Myers Squibb Company

Currency

USD

Beta

0.415642

Vol Avg

8118334

Ceo

Dr. Giovanni Caforio M.D.

Cik

0000014272

Cusip

110122108

Exchange

New York Stock Exchange

Full Time Employees

34300

Industry

Drug Manufacturers—General

Sector

Healthcare

Ipo Date

1972-06-01

Address

430 East 29th Street

City

New York

State

NY

Country

US

Zip

10016

Phone

212 546 4000

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies